Abstract:The tumor suppressor p53 plays a key role in the regulation of cell cycle, apoptosis, DNA repair, and senescence. It acts as a transcriptional factor, and is able to activate various genes to exert specific functions. MDM2, the main regulator of p53, inhibits the function of p53 through direct interaction. On the basis of this finding, inhibiting the MDM2-p53 interaction can be a potentially important target for cancer therapy. We showed here that L2, an analog of small-molecule MDM2 antagonist nutlins, stabilized p53 and selectively activated the p53 pathway in p53 wild-type A549 cells, resulting in a pronounced antiproliferation effect through inducing cell cycle arrest and apoptosis. Meanwhile, we confirmed by immunoprecipitation analysis that L2 could also inhibit MDM2-p53 interaction, similar to nutlin-1. Real-time PCR results revealed that L2 had no effect on the p53 gene transcriptional level, but it could induce the upregulation of p21 at the transcriptional level, which was the downstream of p53. Therefore, we concluded that the accumulation of p53 caused by L2 was mainly because of the decrease of the protein degradation rather than the elevation of p53 gene expression. Furthermore, no phosphor-p53 formed after L2 treatments, indicating that a genetoxic mechanism was unlikely to contribute to the activation of p53 by L2. In conclusion, the data acquired from A549 cells indicated that L2 exhibited high anti proliferation activity by disrupting MDM2-p53 interaction, and that the mechanism was derived from the activation of p53 and the p53 pathway. It was also surprising that L2 showed high anti proliferation effect against p53 null H L60 cells, which was quite different from nutlin-1. G(2)/M phase arrest might have contributed to the high anti proliferation activity of L2 on HL60 cells. The changes of p53 and MDM2 protein levels in L2-treated HL60 cells indicated that the mechanisms involved in the cell cycle arrest in A549 and HL60 cells were probably different, to which our future research would be devoted. Anti-Cancer Drugs 20:416-424 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

Lidamycin regulates p53 expression by repressing Oct4 transcription.

Lidamycin Induces Neural Differentiation of Mouse Embryonic Carcinoma Cells Through Down-Regulation of Transcription Factor Oct4.

Inhibition of Mouse Embryonic Carcinoma Cell Growth by Lidamycin Through Down-Regulation of Embryonic Stem Cell-Like Genes Oct4, Sox2 and Myc

Negative Regulation of p53 Functions by Daxx and the Involvement of MDM2

DEPTOR is a Direct P53 Target That Suppresses Cell Growth and Chemosensitivity

P53 Dependent and Independent Apoptosis Induced by Lidamycin in Human Colorectal Cancer Cells

Inhibitory Effect of Low-Dose Lidamycin on Growth of P19 Embryonal Carcinoma Cells and Its Mechanism

JMJD5 Interacts with P53 and Negatively Regulates P53 Function in Control of Cell Cycle and Proliferation.

LMO4 inhibits p53-mediated proliferative inhibition of breast cancer cells through interacting p53

A p53/LINC00324 positive feedback loop suppresses tumor growth by counteracting SET-mediated transcriptional repression

Loss of VGLL4 Suppresses Tumor PD-L1 Expression and Immune Evasion

Role of Prosurvival Molecules in the Action of Lidamycin Toward Human Tumor Cells

Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.

Microrna-1827 Represses MDM2 to Positively Regulate Tumor Suppressor P53 and Suppress Tumorigenesis

A p53/lnc‐Ip53 Negative Feedback Loop Regulates Tumor Growth and Chemoresistance

Negative Regulation Of Hdm2 To Attenuate P53 Degradation By Ribosomal Protein L26

Specific zinc finger-induced methylation of PD-L1 promoter inhibits its expression.

A naturally derived small molecule compound suppresses tumor growth and metastasis in mice by relieving p53-dependent repression of CDK2/Rb signaling and the Snail-driven EMT

p,p′-Dichlorodiphenyltrichloroethane inhibits the apoptosis of colorectal adenocarcinoma DLD1 cells through PI3K/AKT and Hedgehog/Gli1 signaling pathways

Inactivation of Oncogenic Camp-Specific Phosphodiesterase 4D by Mir-139-5p in Response to P53 Activation

Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells